What do systematic reviews say?

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in symptom free with activities of daily living (patient rated) ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 1.92 [0.92, 4.1]
  1 study · 57 participants
  Low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.37, 3.77]
  1 study · 39 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.63 [0.12, 3.38]
  1 study · 39 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 2.5 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.56 [0.23, 1.37]
  1 study · 40 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2 [0.2, 20.33]
  1 study · 40 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

The review found no eligible studies for this question.

• Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found